Franklin Resources Inc Tg Therapeutics, Inc. Transaction History

Franklin Resources Inc

$313 Billion
Q2 2024

A detailed history of Franklin Resources Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 124,229 shares of TGTX stock, worth $3.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

124,229

Previous 117,017 6.16%

Holding current value

$3.14 Million

Previous $1.78 Million 24.23%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $96,063 - $138,398	7,212 Added 6.16%	124,229 $2.21 Million
Q1 2024 May 13, 2024	BUY	$13.02 - $21.3 $678,224 - $1.11 Million	52,091 Added 80.23%	117,017 $1.78 Million
Q4 2023 Feb 09, 2024	BUY	$6.68 - $18.81 $202,550 - $570,356	30,322 Added 87.63%	64,926 $1.11 Million
Q3 2023 Nov 13, 2023	SELL	$8.36 - $26.5 $299,371 - $948,965	-35,810 Reduced 50.86%	34,604 $289,000
Q2 2023 Aug 11, 2023	BUY	$15.48 - $35.0 $1.09 Million - $2.46 Million	70,414 New	70,414 $1.75 Million
Q4 2018 Feb 12, 2019	SELL	$3.44 - $5.76 $6.51 Million - $10.9 Million	-1,892,978 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$5.15 - $14.0 $2.02 Million - $5.48 Million	-391,499 Reduced 17.14%	1,892,978 $10.6 Million
Q2 2018 Aug 14, 2018	SELL	$12.5 - $15.0 $1.62 Million - $1.94 Million	-129,220 Reduced 5.35%	2,284,477 $30 Million
Q1 2018 May 10, 2018	SELL	$8.7 - $16.8 $380,346 - $734,462	-43,718 Reduced 1.78%	2,413,697 $34.3 Million
Q4 2017 Feb 14, 2018	BUY	$7.35 - $12.3 $642,375 - $1.07 Million	87,398 Added 3.69%	2,457,415 $20.2 Million
Q3 2017 Nov 13, 2017	BUY	$10.0 - $12.7 $23.7 Million - $30.1 Million	2,370,017	2,370,017 $28.1 Million

Others Institutions Holding TGTX

# of Institutions

287

Shares Held

91.8M

Call Options Held

1.9M

Put Options Held

1.45M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $3.67B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Account

Franklin Resources Inc Tg Therapeutics, Inc. Transaction History